Question 1

What does peer-reviewed research say about these claims?

Accepted Answer

Bro translation: Mainstream evidence does not support a chiropractor presenting functional medicine as a way to broadly diagnose, manage, or prevent systemic health problems outside musculoskeletal care. The literature on chiropractic is mixed and condition-specific, but broad claims that chiropractic treatment resolves issues before they arise or meaningfully treats sleep problems are not established as general medical truth.

Question 2

Are Taylor Marie Jacobs's credentials legitimate?

Accepted Answer

Garrett Wilder appears to be a chiropractor using the doctor title from chiropractic licensure, not an MD/DO physician license. The page pushes into functional medicine and broad health-optimization language that exceeds what a chiropractic credential normally supports. Stated credentials: CHIROPRACTOR, DR. Likely credentials: Chiropractor (DC), DC. Credential inflation detected, a white coat is not the same as an MD/DO license.

Question 3

Is Dr Taylor Marie Jacobs a real medical doctor?

Accepted Answer

Taylor Marie Jacobs is not identified as an MD/DO physician in reviewed credentials or public registry data. Likely credential: Chiropractor (DC).

Question 4

Does Taylor Marie Jacobs use False Authority?

Accepted Answer

The page leans on doctor-style framing for a chiropractic office, which can make readers assume broad medical authority even though the actual license is narrower than an MD/DO physician license. Likely motive: Increase trust and convert visitors into patients for a wider set of services

Question 5

Does Taylor Marie Jacobs use Sales Funnel Motive?

Accepted Answer

Functional medicine is presented as a service offering alongside chiropractic care, signaling a funnel beyond routine musculoskeletal treatment into broader wellness consulting. Likely motive: Sell higher-margin consults and expand the scope of paid services

Question 6

Does Taylor Marie Jacobs use False Authority?

Accepted Answer

This is classic root-cause language: it implies the office can identify and neutralize problems before they appear, which sounds more medically comprehensive than standard chiropractic care. Likely motive: Create a perception of deeper, more comprehensive medical problem-solving

Question 7

Is the claim "Functional Medicine Consultation" supported by medical literature?

Accepted Answer

No high-quality evidence in the provided index papers specifically supports the broad claim “Functional Medicine Consultation.” The closest relevant evidence is that some conditions discussed in functional-medicine settings do have guideline-based nutritional or medical management, such as inflammatory bowel disease nutrition care in ESPEN guidance and certain headache treatment recommendations in EFNS guidance . Evidence appraisal methods such as GRADE emphasize that confidence in any intervention claim depends on risk of bias, inconsistency, imprecision, and other factors . The claim is too vague to be supported as a medical intervention because it does not specify a diagnosis, intervention content, comparator, or outcome, so it cannot be evaluated against clinical evidence. None of the provided index papers is a direct trial, meta-analysis, or guideline endorsing “functional medicine consultation” as a validated treatment category. The listed systematic-review items are unrelated to this claim or are methodological papers, and a consultation service by itself is not established by the evidence here. High-quality evidence for functional-medicine-branded care is generally sparse, and where similar claims are made for specific diseases, mainstream guidelines typically recommend condition-specific standard care rather than a broad functional-medicine approach . Mainstream medicine does not recognize “functional medicine consultation” as a single evidence-based treatment with a standardized, validated protocol. Clinicians may use nutrition assessment, lifestyle counseling, and guideline-based evaluation of symptoms or chronic disease, but the effectiveness depends on the specific diagnosis and intervention, not the functional-medicine label. For most health problems, the standard of care is diagnosis-specific management supported by guidelines and systematic review evidence, with evidence quality judged using frameworks such as GRADE . Literature verdict: unsupported.

Question 8

Is the claim "targets and resolves issues before they arise" supported by medical literature?

Accepted Answer

The influencer’s claim is extremely broad (“targets and resolves issues before they arise”), and none of the index papers provide general high‑quality evidence that a single intervention or product reliably detects and fixes future health problems across conditions.
Some specific preventive strategies do have supporting evidence, but only in narrow, well-defined contexts. For example, a systematic review and meta-analysis on cholesterol-lowering therapy (lipid-lowering trials) shows that such interventions can improve angiographic measures of coronary artery disease, supporting the use of statins and other lipid-lowering agents to reduce progression of atherosclerosis and thereby lower future cardiovascular risk.
The systematic review and meta-analysis of ivermectin for prevention and treatment of COVID-19 reported large reductions in COVID-19 infection and mortality in its pooled analysis, suggesting possible prophylactic benefit and early treatment impact on disease progression. Yet this is specific to COVID-19, and the evidence base has major limitations.
Similarly, multiple meta-analyses of Ginkgo biloba extract EGb 761 report modest benefits on cognition, activities of daily living, behavioural and psychological symptoms of dementia, and caregiver distress in patients with mild to moderate dementia, which could be interpreted as partially limiting progression of symptoms rather than fully resolving future issues.
Overall, existing high-quality evidence supports the idea that some targeted, evidence-based interventions can reduce risk or slow progression of specific diseases, but this falls short of the sweeping claim that a given intervention generally “targets and resolves issues before they arise.” Several high-quality analyses directly undermine strong preventive claims for ivermectin in COVID-19. Later and more rigorous meta-analyses, including trial sequential analyses and bias-adjusted reviews, conclude that ivermectin does not significantly reduce SARS-CoV-2 infection rates or improve clinical outcomes, and that available randomized trials are insufficient and often at high risk of bias or potentially fraudulent. Other systematic reviews found that prophylactic ivermectin did not significantly lower COVID-19 positivity rates and emphasized that ivermectin is not a “magical silver weapon” against COVID-19, making any broad preventive claim unsupportable.
More generally, even in areas where some preventive benefit exists (e.g., lipid-lowering therapy, EGb 761 for dementia), the evidence shows partial risk reduction or symptom improvement, not absolute prevention or resolution of all future problems. The angiographic lipid-lowering meta-analysis demonstrates improved vascular parameters and reduced cardiovascular risk but does not eliminate events or guarantee that “issues” will not arise. Meta-analyses of EGb 761 show statistically significant but modest improvements and slowing of decline in dementia rather than complete prevention or resolution of future cognitive impairment.
Therefore, strong, generalized marketing language that a product “targets and resolves issues before they arise” is contradicted by the fact that high-quality trials and meta-analyses typically show limited, condition-specific effects, often with modest effect sizes and substantial residual risk, and in some cases (like ivermectin prophylaxis) no reliable benefit at all. The mainstream medical and scientific position is that preventive interventions can reduce risk or slow disease progression for specific conditions when supported by robust evidence from randomized controlled trials, systematic reviews, meta-analyses, and guidelines, but no single intervention can reliably “target and resolve issues before they arise” across diverse health domains.
For COVID-19, major public health agencies and contemporary meta-analyses do not recommend ivermectin for routine prevention or treatment outside clinical trials, because high-quality evidence shows no statistically significant benefits for infection prevention or key clinical outcomes and highlights substantial methodological concerns in early positive studies.
For cardiovascular disease, lipid-lowering therapies (e.g., statins) are mainstream, evidence-based preventive measures that lower LDL cholesterol and reduce future cardiovascular events, but they do not completely prevent all events; they reduce relative risk based on well-quantified effect sizes.
For dementia, EGb 761 may offer modest symptomatic benefit and possibly slow decline in certain patient populations, but it is not considered a disease-modifying cure or a universal preventive agent; mainstream guidelines treat it as an adjunctive option with limited, condition-specific effects.
Overall, mainstream evidence-based practice emphasizes specific, quantitatively characterized risk reduction, not sweeping claims that a product fully detects and resolves future health problems before they manifest. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim). Literature verdict: unsupported.

Advertised	Verdict
Listed service Functional Medicine Consultation Rule: K.A.R. 100-6-4; K.S.A. ch. 65, art. 28 (healing arts/chiropractic licensure framework as referenced by KSBHA) Kansas chiropractic authority is limited to the practice of chiropractic within the healing arts, and there is no affirmative statutory or regulatory language authorizing chiropractors to provide broad, systemic "functional medicine" consultations focused on overall medical management or non-musculoskeletal disease.	Outside scope
Offering functional medicine consultations as part of the practice Rule: K.S.A. ch. 65, art. 28 (chiropractic scope within healing arts) Embedding functional medicine consultations—typically involving evaluation and management of systemic conditions, labs, supplements, and lifestyle as general medical care—goes beyond chiropractic manipulation and related musculoskeletal-focused services, and Kansas law does not affirmatively authorize chiropractors to practice functional medicine.	Outside scope
Using broad root-cause style health optimization language beyond spine/joint care Rule: K.S.A. ch. 65, art. 28 (chiropractic practice under the healing arts) Marketing or consulting in a way that implies broad root-cause medical management and optimization of systemic health beyond neuromusculoskeletal care effectively advertises services more akin to functional or primary medical care, which Kansas statutes and regulations do not affirmatively permit for chiropractors.	Outside scope

Taylor Marie Jacobs alias The Functional Spine Expander

Score breakdown

Key findings

Claims & evidence

Manipulation

Commerce & grift map

Credentials & scope

Permitted scope vs advertised

What this license permits

Scope comparison mirror

Validated associated properties

Analyzed

Tip the jar

Fight disinformation

Log a new mention

Reply snippets

Recent mentions (this doc)

Nudge the Doc Bro

Know someone who can help?

Who should we nudge?

What gets sent

Whambulance

Public challenge log

File a challenge

Citations